Incyte Corporation (LON:0J9P)

Market Cap	11.14B
Revenue (ttm)	3.35B
Net Income (ttm)	635.65M
Shares Out	n/a
EPS (ttm)	3.19
PE Ratio	17.53
Forward PE	12.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	348
Average Volume	716
Open	75.50
Previous Close	76.10
Day's Range	74.24 - 75.50
52-Week Range	53.61 - 83.54
Beta	0.68
RSI	61.46
Earnings Date	Jul 29, 2025

About Chuy's Holdings

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1991
• Employees: 2,617
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0J9P

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.